PUBLICATIONS AND PATENTS
Michael W. Konrad
PUBLICATIONS
——2021
Preprint: Entrainment of Chaotic Oscillations in a Colonial Tunicate. Konrad, Michael W.
https://www.researchsquare.com/article/rs-655370/v2
—-2016
Blood Circulation in the Ascidian Tunicate Corella inflata (Corellidae). Konrad MW PeerJ 4:2771;DOI10.7717/peerj.2771
—-2005
Book (softback): Life on the Dock. Publisher: Science Is Art; available at Amazon.com
——1996
Molecular Dynamics Simulation of DNA Stretching is Consistent with the Tension Observed for Extension and Strand Separation and Predicts a Novel Ladder Structure. Konrad MW and Bolonick JI. J Am Chem Soc 118:10986-10994 (1996)
Infusible Platelet Membrane Microvesicles: a Potential Transfusion Substitute for Platelets. Chao FC, Kim BK, Houranieh AM, Liang FH, Konrad MW, Swisher SN, Tullis JL. Transfusion 36:536-542 (1996)
——1993
Chapter 14. The Immune System as a Barrier to the Delivery of Protein Therapeutics. Konrad MW, in Pharmaceutical Biotechnology, Vol. 5, pp409-437, Biological Barriers to Protein Delivery. Audus and Raub, eds., Plenum Publishing Corporation, New York (1993)
——1992
Suppression and Transient Induction of Lymphokines in Cancer Patients after Administration of Pegylated Interleukin-2. Shih Y, Konrad MW, Warren K, Childs A, Paradise C, Meyers FJ,Groves EC. Eur J Immunol 22:727-733 (1992)
Gamma IFN Induced by Administration of Recombinant IL-2 to Cancer Patients: Kinetics, Dose Dependence, and Correlation with Physiological and Therapeutic Response. Konrad MW, DeWitt SK, Bradley EC, Goodman G, Groves EC, Hersh EM, Kriegle RL, Rudolph A. J Immunother 12:55-63 (1992)
A Phase I Trial of Recombinant Human Macrophage Colony Stimulating Factor. Zamkoff KW, Hudson J, Groves ES, Childs A, Konrad M, Rudolph AR. J Immunother 11:103-110 (1992)
——1991
A Phase I Study Including Pharmacokinetics of Polyethylene Glycol Conjugated Interleukin 2. Meyers FJ, Paradise C, Scudder SA, Goodman G, Konrad M. Clin Pharm Therapeutics 49:307-313 (1991)
Detection and Quantification of Human Immunodeficiency Virus RNA in Patient Serum by the Use of the Polymerase Chain Reaction. Holodniy M, Katzenstein DA, Sengupts S, Wang AM, Casipit C, Schwartz DH, Konrad M, Groves E, Merigan TC. J Inf Dis 163:862-866 (1991
Inhibition of Human Immunodeficiency Virus Gene Amplification by Heparin. Holodniy M, Kim S, Katzenstein D, Konrad M, Groves E, Merigan TC. J Clin Microbiol 29:676-670 (1991)
Hemorrhagic Gastritis as a New Dose-Limiting Toxicity of Recombinant Tumor Necrosis Factor. Krigel RL, Padavic-Shaller KA, Rudolph AR, Young JD, Weiner LM, Konrad M, Comis, RL. J Natl Cancer Inst 83:129-131 (1991)
——1990
Renal Cell Carcinoma: Treatment with Recombinant Interleukin-2 Plus Beta-Interferon. Krigel RL, Padavic-Shaller KA, Rudolph AR, Konrad M, Bradley EC, Comis RL. J Clin Oncology 8:460-467 (1990)
Pharmacokinetics of Recombinant Interleukin 2 in Humans. Konrad MW, Hemstreet G, Hersh EM, Mansell PWA, Mertelsmann R, Kolitz JE, Bradley EC. Cancer Res. 50:2009-2017 (1990)
Subcutaneous Recombinant Interleukin 2 in a Dose Escalating Regimen in Patients with Metastatic Renal Cell Adenocarcinoma. Whitehead RP, Ward D, Hemingway L, Hemstreet III GP, Bradley E, Konrad M. Cancer Res. 50:6708-6715 (1990)
——1989
Phase I Study of Recombinant Interleukin-2 and Recombinant beta Interferon in Refractory Neoplastic Disease. Paolozzi F, Zamkoff K, Doyle M, Konrad M, Bradley EC, Rudolph A, Newman N, Gullo J, Scalzo A, Poiesz B. J Biol Response Mod. 8:122-139 (1989)
REVIEW: Immunogenicity of Proteins Administered to Humans for Therapeutic Purposes. Michael Konrad. Trends in Biotechnology 7:175-179 (1989)
Phase I Study of Cancer Therapy with Recombinant Interleukin-2 Administered by Intravenous Bolus Injection. Hersh, EM, Murray JL, Hong WK, Rosenblum MG, Reuben JM, Weilbaecher R, Sarwal AN, Bradley EC, Konrad M, Arnett FC. Biotherapy 1:215-226 (1989)
Phase I Evaluation of an Anti-breast Carcinoma Monoclonal Antibody 260F9-recombinant Ricin A Chain Immunoconjugate. Weiner LM, O'Dwyer J, Kitson J, Comis RL, Frankel AE, Bauer RJ, Konrad MW, Groves ES. Cancer Res 49:4062-4067 (1989)
——1988
A Phase I Study of Recombinant Interleukin-2 Plus Recombinant beta Interferon. Krigel RL, Padavic-Shaller KA, Rudolph AR, Litwin S, Konrad MW, Bradley EC, Comis RL, Cancer Res 48:3875-381 (1988)
A Phase I Trial of Intraperitoneal Recombinant Interleukin 2 in Patients with Overian Carcinoma. Chapman PB, Kolitz JE, Hakes TB, Gabrilove JL, Welte K, Merluzzi VJ, Engert A, Bradley EC, Konrad M, Mertelsmann R. Investigational New Drugs 6:179-188 (1988)
A Phase I Evaluation of the Ricin A Chain Anti-breast Carcinoma Immunoconjugate 290F9 MAB-rRA. Weiner LM, Odwyer J, Kitson J, Comis RL, Groves E, Konrad MW. Clinical Res. 36(5):803 (1988)
Phase I Trial of Recombinant Interleukin-2 and Cyclophosphamide: Augmentation of Cellular Immunity and T-cell Mitogenic Response with Long-term Administration of rIL-2. Kolitz JE, Wong GY, Welte K, Merluzzi VJ, Engert A, Bialas T, Polivka A, Bradley EC, Konrad M, Gnecco C. J Biol Response Mod 7:457-472 (1988)
——1987
Regulation by Recombinantn Interleukin-2 of Protective Immunity against Recurrent Herpes Simplex Virus Type 2 Genital Infection in Guinea Pigs. Weinberg A, Konrad MW, Merigan TC, J Virol 61:2120-2127 (1987)
Assessment of the Antigenic Response in Humans to a Recombinant Mutant Interferon Beta. Konrad MW, Childs AL, Merigan TC, Borden EC J Clin Immunol 7:365-375 (1987)
Expansion of Activated T-Lymphocytes in Patients Treated with Recombinant Interleukin 2. Kolitz JE, Welte K, Wong GY, Holloway K, Merluzzi VJ, Engert A, Bradley EC, Konrad MW, Polivka A, Gabrilove JL, Sykora, Miller GA, Fiedler W, Krown S, Oettgen HF, Mertelsmann R J Biol Response Mod 6:412-429 (1987)
BOOK REVIEW: Biotechnology- the University Industrial Complex. by Martin Kenney, Konrad MW, J Genet 66:221-223 (1987)
——1986
The Development of Anti-Interleukin-2 Antibodies in Patients Treated with Recombinant Human Interleukin-2 (IL-2). Allegretta M, Atkins MB, Dempsey RA, Bradley EC, Konrad MW, Childs A, Wolfe SN, Mier JW, J Clin Immunol 6:481-490 (1986)
Preliminary Trial of recombinant Fibroblast Interferon in Chronic Hepatitis B Virus Infection. Eisenberg M, Rosno S, Garcia G, Konrad MW, Gregory PB, Robinson WS, Merigan TC, Antimicrobial Agents Chemotherapy 29:122-126 (1986)
Extended Phase I Study of Human beta-Interferon in Human Cancer. Abdi EA, Kamitomo VJ, McPherson TA, Konrad MW, Inoue M, Tan YH. Clin Invest Med 9:33-40 (1986)
1985
Interferon Betaser : Interim Analysis of a Phase I Clinical Trial. Hawkins M, Horning S, Konrad MW, Anderson S, Schiessel J, Sielaff K, Rosno S, Demets D, Merigan T, Borden E, in The Biology of the Interferon System, Elsevier Science Pub. 503-508 (1985)
Phase I Evaluation of a Synthetic Mutant of beta-Interferon. Hawkins M, Horning S, Konrad MW, Anderson S, Sielaff K, Roso S, Schiesel J, Davis T, Demets D, Merigan T, Borden E, Cancer Res 45:5914-5920 (1985)
——1984
Formation of Islet Hormans. Steiner DF, Chan SJ, Kwok SC, Konrad MW, Patzelt C, Schwartz T, Tager HS, Rubenstein A, in Recent Advances in Obesity and Diabetes Research, Raven Press, 8:175-190 (1984)
Expression of a beta-lactamase Preproinsulin Fusion Protein in Escherichia coli, Emerick AW, Bertolani BL, Ben-Bassat A, White TJ, Konrad MW. Biotechnology 2:165-168 (1984)
——1983
Applications of Genetic Engineering to the Pharmaceutical Industry. Konrad MW, Ann N Y Acad Sci 413:12-22 (1983)1968
Dependence of "Early" Lambda Bacteriophage RNA Synthesis on Bacteriophage-directed Protein Synthesis. Konrad MW, Proc Nat Acad Sci (USA) 59:171-178 (1968)1975
The 5'-termini of Bacterial RNA, I. The Monophosphorylated Termini. Cook JC, Konrad MW, Biochem Biophys Acta 383:399-409 (1975)
——1982
Growth of Mouse Mammary Gland End Buds Cultured in a Collagen Gel Matrix. Richard J, Guzman R, Konrad MW, Yang J, Nandi S, Expt Cell Res 141:433-443 (1982)
——1981
Biosynthesis and Periplasmic Segregation of Human Proinsulin in Escherichia coli. Chan SJ, Weiss J, Konrad MW, White T, Bahl C, Yu S-D, Mark D, Steiner DF. Proc Nat Acad Sci (USA) 78:5401-5405 (1981)
——1980
Arrested Growth of Chinese Hanster Ovary (CHO) Cell Colonies on Agar. Storrie B, Konrad MW, Glaser DA, Cell and Tissue Kinetics 13:263-276 (1980)
A Grey Level Frequency Histogram Representation of Animal Cell Colonies Seen by Scattered Light. Konrad MW, Couch JL, Glaser DA. Comp Biomed Res 13:333-349 (1980)
Chemical Carcinogenesis of Mammary Epithelium in Cell Culture. Richards J, Guzman R, Yang J, Nandi S, Konrad MW. in Cell Biology of Breast Cancer, Academic Press, NY, 467-484 (1980)
——1979
Growth and Morphology of Colonies of CHO Cells Growing on Agar is Affected by Insulin. Aidells B, Konrad MW, Glaser DA, Proc Nat Acad Sci (USA) 76:1863-1867 (1979)
Analysis of Images of Colonies of Tissue Culture Cells and Microorganisms. Couch JL, Konrad MW, Glaser DA. in Pattern Recognition and Image Processing 1979, IEEE Press, 473-478 (1979)
——1977
Clonal Variation in Colony Morphology and Growth of CHO Cells Cultured on Agar. Konrad MW, Storrie B, Glaser DA, Thompson LH, Cell 10:305-312 (1977)
——1976
The 5'-termini of Bacterial RNA, II. The Triphosphate-terminated Ends of Primary gene transcripts. Konrad MW, Toivonen, Cook JC, Biochem Biophys Acta 525:63-75 (1976)
——1974
Apparent Average Length of the Transcripional Unit in Bacteria. Konrad MW, J Bact 119:228-241 (1974)
Stimulation of RNA Chain Initiation by the N Protein of Bacteriophage Lambda. Wood KC, Konrad MW, Mol Gen Genet 134:359 -366(1974)
——1973
Alkaline Hydrolysis of Oligonucleotides on Chromatographic Paper. Konrad MW, Anal Biochem 54:213-222 (1973)
The Kinetics of Phosphate Incorporation into ATP and GTP in Bacteria. Lutkenhaus J, Ryan J, Konrad MW, J Bact 116:1113-1123 (1973)
——1972
Initial Nucleotide Frequencies of Bacterial RNA Synthesized During Amino Acid Starvation or Changes in Carbon Source. Konrad MW, Toivonen J, Nierlich D, Nature New Biol 238:231-233 (1972)
——1970
Gene Expression in Bacteriophage Lanbda I. The Kinetics of the Requirement for N Gene Product. Robovsky D, Konrad MW, Virology 40:10-17 (1970)
Gene Expression in Bacteriophage Lambda II. Regulation of RNA Synthesis in vivo by the N Protein. Konrad MW J Mol Biol 53:389-400 (1970)
——1966
Direction of Chain Growth in Enzymatic RNA Synthesis. Bremer H, Konrad MW, Gains, Stent GS, J Mol Biol 13:540-553 (1966)
Inactivation of Purified E coli RNA Polymerase by Transfer RNA. Bremer H, Yegian C, Konrad MW, J Mol Biol 16:94 -103(1966)
Capacity of T4 DNA to Serve as Template for Purified E coli RNA Polymerase. Bremer H, Konrad MW, Bruner R, J Mol Biol 16:104117 (1966)
——1965
Transfer Distribution of the DNA of T4 Over Its Progeny. Konrad MW, Stent GS, Z. Verebungsl 96:66-82 (1965)
——1964
On "Natural" DNA-RNA Complexes in Phage Infected E. coli. Konrad MW, Stent GS, Proc Nat Acad Sci (USA) 51:647-653 (1964)
A Complex of Enzymatically Synthesized RNA and Template DNA. Bremer H, Konrad MW, Proc Nat Acad Sci (USA) 51:801-803 (1964)
-1960
The Mutagenic Effect of D2O on Bacteriophage T4. Konrad MW, N Y Acad Sci 84:678-684 (1960)
PATENTS
US Patent 4,450,103 "Process for Recovering Human beta IFN from a Transformed Microorganism"
US Patent 4,499,188 "A Process for Bacterially Producing a Heterologous Polypeptide Comprising Cultivating Bacteria Transformaed to Express Said Heterologous Polypeptide Under the Control of a Bacterial Promotor Operator"
US Patent 5,789.167 “Optical Detection of Position of Oligonucleotides on Large DNA Molecules”
SELECTED PRESENTATIONS
Infusible Platelet Membrane (IPM) is a Potential Substitute for Fresh Platelets in the Transfusion Correction of Prolonged Bleeding Time in Thrombocytopenic Rabbits. Chao, FC, Kim, BB, Houranieh, AM, Liang, FH, Tullis, JL, Swisher, SN, Konrad, MW. Presented at XIVth Congress of the International Society on Thrombosis and Haemostasis, July 1993
Visual Genetic Mapping: A New Technique. Konrad MW. Poster presented at The Human Genome Project, San Francisco, March 1995
Field Assisted Hybridization. Konrad MW. Poster presented at Microfabrication Technology for Research and Diagnostics, San Francisco, September 1995